PRECISE: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization

Grants and Contracts Details

StatusActive
Effective start/end date3/22/197/13/23

Funding

  • HeartFlow Incorporated: $69,911.00